美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

CITIUS ONCOLOGY INC

0.8396

-0.0003-0.04%

成交量：1.25萬

成交額：1.02萬

市值：7,806.70萬

市盈率：-1.75

高：0.8396

開：0.8301

低：0.8000

收：0.8399

52周最高：6.19

52周最低：0.4912

股本：9,298.12萬

流通股本：1,412.60萬

量比：1.21

換手率：0.09%

股息：- -

股息率：- -

每股收益(TTM):-0.4800

每股收益(LYR):-0.3380

淨資產收益率：-119.90%

總資產收益率：-28.31%

市淨率：2.21

市盈率(LYR):-2.48

資料載入中...

總覽公司新聞資訊公告

Citius Oncology, Inc. 獲得高達3650萬美元債務及股權資本，以加速Lymphir®商業化進程

Citius Oncology公布Lymphir™聯合帕博利珠單抗治療復發或難治性婦科癌研究者發起的1期研究積極頂線結果

BUZZ-Citius公司因淋巴瘤藥物在接受CAR-T療法前顯示出對患者的益處而上漲

Citius Oncology Inc一期臨床試驗顯示：總體緩解率達86%，完全緩解率57%，部分緩解率29%

Lymphir在I期研究中耐受性良好，未觀察到劑量限制性毒性

Citius Oncology公布Lymphir™（E7777）在高危瀰漫性大B細胞淋巴瘤商用CAR-T療法前給藥的1期研究初步頂線數據

Citius Oncology與Uniphar達成獨家協議將淋巴瘤藥物Lymphir™分銷版圖擴展至歐盟

Citius Oncology, Inc.盤中異動早盤股價大跌5.42%

Citius Oncology, Inc.盤中異動大幅拉升5.61%

Citius Oncology, Inc.盤中異動早盤急速下挫6.96%

Citius Oncology, Inc.盤中異動早盤大幅下挫5.31%報1.07美元

Citius Oncology完成1800萬美元的同時註冊直接發行和私募配售，價格符合納斯達克規則

Citius Oncology Inc - 直接發行以每股1.09美元購買1,284,404股普通股

Citius Oncology 宣佈以市場定價進行1800萬美元的註冊直銷及私人投資

Citius Oncology通過與Er-Kim的獨家協議擴展Lymphir™在土耳其和中東國家的分銷

Citius Oncology 宣佈 Lymphir™ 上市，作為切膚性 T 細胞淋巴瘤的新型癌症免疫療法

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CTOR/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTOR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","market":"US","secType":"STK","nameCN":"CITIUS ONCOLOGY INC","latestPrice":0.8396,"timestamp":1779805545659,"preClose":0.8399,"halted":0,"volume":12466,"delay":0,"changeRate":-0.0003571853792117716,"floatShares":14126000,"shares":92981204,"eps":-0.48,"marketStatus":"交易中","change":-0.0003,"latestTime":"05-26 10:33:57 EDT","open":0.8301,"high":0.8396,"low":0.8,"amount":10161.2678443,"amplitude":0.047148,"askPrice":0.8792,"askSize":100,"bidPrice":0.82,"bidSize":26,"shortable":3,"etf":0,"ttmEps":-0.48,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1779825600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.8399,"preHourTrading":{"tag":"盘前","latestPrice":0.8699,"preClose":0.8399,"latestTime":"08:58 EDT","volume":2814,"amount":2442.6442992,"timestamp":1779800334858,"change":0.03,"changeRate":0.035719,"amplitude":0.035719},"postHourTrading":{"tag":"盘后","latestPrice":0.8399,"preClose":0.8399,"latestTime":"16:15 EDT","volume":5,"amount":4.1896,"timestamp":1779480951219,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.211183},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","floatShares":14126000,"roa":"-28.31%","roe":"-119.90%","lyrEps":-0.337956,"volumeRatio":1.211183,"shares":92981204,"dividePrice":0,"high":0.8396,"amplitude":0.047148,"preClose":0.8399,"low":0.8,"week52Low":0.4912,"pbRate":"2.21","psRate":"13.91","week52High":6.19,"institutionHeld":0,"latestPrice":0.8396,"committee":-0.587302,"eps":-0.48,"divideRate":0,"volume":12466,"delay":0,"ttmEps":-0.48,"open":0.8301,"prevYearClose":1,"prevWeekClose":0.8399,"prevMonthClose":0.8799,"prevQuarterClose":0.6199,"fiveDayClose":0.8289,"twentyDayClose":0.8735,"sixtyDayClose":1.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTOR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-15","symbol":"CTOR","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2026-02-13","symbol":"CTOR","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1770958800000,"reportTimeType":"pre","actualEps":-0.06},{"market":"US","date":"2025-12-23","symbol":"CTOR","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1766466000000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2025-08-12","symbol":"CTOR","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.08}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTOR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTOR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1758859200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTOR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTOR","date":"2026-05-22","current":-1.749792,"percent":0.993182,"low":-14.569058,"twenty":-5.514142,"median":-3.957191,"eighty":-2.91411,"high":-1.715236,"avg":-4.318505,"sd":1.838045,"marketCap":73180144},"quantilePoints":[{"date":"2024-08-23","current":-7.506449,"twenty":-8.175502,"median":-7.996,"eighty":-7.800179,"marketCap":131199450},{"date":"2024-08-30","current":-6.464428,"twenty":-8.028637,"median":-7.567643,"eighty":-6.639734,"marketCap":126208166},{"date":"2024-09-06","current":-6.847911,"twenty":-7.922567,"median":-7.149219,"eighty":-6.405992,"marketCap":133695091},{"date":"2024-09-13","current":-5.989639,"twenty":-7.726747,"median":-6.50095,"eighty":-6.274513,"marketCap":116938640},{"date":"2024-09-20","current":-6.099206,"twenty":-7.555404,"median":-6.464428,"eighty":-5.97503,"marketCap":119077761},{"date":"2024-09-27","current":-5.222673,"twenty":-7.472896,"median":-6.354861,"eighty":-5.953117,"marketCap":101964790},{"date":"2024-10-04","current":-4.309619,"twenty":-7.088957,"median":-6.190511,"eighty":-5.617113,"marketCap":84138777},{"date":"2024-10-11","current":-3.542653,"twenty":-6.749301,"median":-6.099206,"eighty":-5.018149,"marketCap":69164927},{"date":"2024-10-18","current":-3.944397,"twenty":-6.661648,"median":-5.953117,"eighty":-4.16353,"marketCap":77008372},{"date":"2024-10-25","current":-4.399098,"twenty":-6.559386,"median":-5.916595,"eighty":-4.331532,"marketCap":85885727},{"date":"2024-10-31","current":-4.419185,"twenty":-6.486341,"median":-5.66094,"eighty":-4.324228,"marketCap":86277899},{"date":"2024-11-08","current":-4.602892,"twenty":-6.464428,"median":-5.16789,"eighty":-4.287705,"marketCap":89864492},{"date":"2024-11-15","current":-3.904222,"twenty":-6.464428,"median":-4.930496,"eighty":-4.287705,"marketCap":76224028},{"date":"2024-11-22","current":-3.564201,"twenty":-6.420601,"median":-4.784407,"eighty":-3.944397,"marketCap":69585621},{"date":"2024-11-29","current":-3.356755,"twenty":-6.347557,"median":-4.693102,"eighty":-3.842134,"marketCap":65535551},{"date":"2024-12-06","current":-5.916595,"twenty":-6.296426,"median":-4.747885,"eighty":-3.776395,"marketCap":115512559},{"date":"2024-12-13","current":-3.907874,"twenty":-6.201468,"median":-4.620605,"eighty":-3.842134,"marketCap":76295332},{"date":"2024-12-20","current":-3.871352,"twenty":-6.164946,"median":-4.528752,"eighty":-3.842134,"marketCap":75582291},{"date":"2024-12-27","current":-3.50613,"twenty":-6.135728,"median":-4.435255,"eighty":-3.725263,"marketCap":68451887},{"date":"2025-01-03","current":-4.012144,"twenty":-6.10651,"median":-4.399098,"eighty":-3.717959,"marketCap":84851818},{"date":"2025-01-10","current":-3.992285,"twenty":-6.033466,"median":-4.399098,"eighty":-3.747177,"marketCap":84431834},{"date":"2025-01-17","current":-4.465946,"twenty":-5.967726,"median":-4.376046,"eighty":-3.723807,"marketCap":94449170},{"date":"2025-01-24","current":-4.296782,"twenty":-5.953117,"median":-4.35308,"eighty":-3.739872,"marketCap":90871550},{"date":"2025-01-31","current":-4.262949,"twenty":-5.953117,"median":-4.346141,"eighty":-3.761786,"marketCap":90156026},{"date":"2025-02-07","current":-4.026118,"twenty":-5.938508,"median":-4.309619,"eighty":-3.767526,"marketCap":85147358},{"date":"2025-02-14","current":-4.330615,"twenty":-5.916595,"median":-4.296782,"eighty":-3.799613,"marketCap":91587074},{"date":"2025-02-21","current":-3.72014,"twenty":-5.901986,"median":-4.296782,"eighty":-3.761786,"marketCap":85862882},{"date":"2025-02-28","current":-3.689139,"twenty":-5.807029,"median":-4.262949,"eighty":-3.720436,"marketCap":85147358},{"date":"2025-03-07","current":-3.162119,"twenty":-5.639027,"median":-4.229116,"eighty":-3.689139,"marketCap":72983450},{"date":"2025-03-14","current":-2.294087,"twenty":-5.507546,"median":-4.152992,"eighty":-3.653403,"marketCap":52948777},{"date":"2025-03-21","current":-1.891071,"twenty":-5.317631,"median":-4.127617,"eighty":-3.617985,"marketCap":43646965},{"date":"2025-03-28","current":-2.030577,"twenty":-5.251891,"median":-4.059951,"eighty":-3.565808,"marketCap":46866823},{"date":"2025-04-04","current":-2.191783,"twenty":-5.220193,"median":-4.053963,"eighty":-3.506186,"marketCap":50587548},{"date":"2025-04-11","current":-1.919282,"twenty":-5.198143,"median":-4.02178,"eighty":-3.38992,"marketCap":44298092},{"date":"2025-04-17","current":-2.002676,"twenty":-5.149629,"median":-4.014793,"eighty":-3.224122,"marketCap":46222851},{"date":"2025-04-25","current":-1.987175,"twenty":-5.113107,"median":-3.992285,"eighty":-3.104751,"marketCap":45865089},{"date":"2025-05-02","current":-2.759104,"twenty":-5.076585,"median":-3.944397,"eighty":-2.759104,"marketCap":63681637},{"date":"2025-05-09","current":-2.619599,"twenty":-4.930496,"median":-3.907874,"eighty":-2.693382,"marketCap":60461779},{"date":"2025-05-16","current":-2.437632,"twenty":-4.930496,"median":-3.890787,"eighty":-2.691522,"marketCap":63331031},{"date":"2025-05-23","current":-2.506208,"twenty":-4.784407,"median":-3.875146,"eighty":-2.619599,"marketCap":65112685},{"date":"2025-05-30","current":-2.451953,"twenty":-4.784407,"median":-3.871352,"eighty":-2.502848,"marketCap":63703103},{"date":"2025-06-06","current":-2.671453,"twenty":-4.755189,"median":-3.805483,"eighty":-2.487546,"marketCap":69405829},{"date":"2025-06-13","current":-4.04849,"twenty":-4.660231,"median":-3.776135,"eighty":-2.502848,"marketCap":105182030},{"date":"2025-06-20","current":-4.268817,"twenty":-4.617062,"median":-3.83483,"eighty":-2.506208,"marketCap":110906223},{"date":"2025-06-27","current":-9.639263,"twenty":-4.842843,"median":-3.873249,"eighty":-2.506208,"marketCap":250433407},{"date":"2025-07-03","current":-14.569058,"twenty":-5.098498,"median":-3.876214,"eighty":-2.511716,"marketCap":378512206},{"date":"2025-07-11","current":-8.950744,"twenty":-5.244587,"median":-3.890787,"eighty":-2.545647,"marketCap":232545306},{"date":"2025-07-18","current":-4.40652,"twenty":-5.303022,"median":-3.909331,"eighty":-2.598329,"marketCap":114483843},{"date":"2025-07-25","current":-5.370447,"twenty":-5.303022,"median":-3.944397,"eighty":-2.622079,"marketCap":139527183},{"date":"2025-08-01","current":-7.246465,"twenty":-5.617113,"median":-3.968341,"eighty":-2.631999,"marketCap":188267172},{"date":"2025-08-08","current":-6.066045,"twenty":-5.92757,"median":-3.993409,"eighty":-2.65122,"marketCap":157599217},{"date":"2025-08-15","current":-5.071831,"twenty":-5.92757,"median":-4.017441,"eighty":-2.668242,"marketCap":134797404},{"date":"2025-08-22","current":-4.806444,"twenty":-5.916595,"median":-4.026118,"eighty":-2.679481,"marketCap":127744051},{"date":"2025-08-29","current":-6.251327,"twenty":-5.92757,"median":-4.051227,"eighty":-2.692266,"marketCap":166145638},{"date":"2025-09-05","current":-5.514142,"twenty":-5.933303,"median":-4.056957,"eighty":-2.700326,"marketCap":146552992},{"date":"2025-09-12","current":-5.938837,"twenty":-5.933303,"median":-4.063335,"eighty":-2.734303,"marketCap":157840405},{"date":"2025-09-19","current":-5.498923,"twenty":-5.933303,"median":-4.134553,"eighty":-2.759104,"marketCap":146148523},{"date":"2025-09-26","current":-5.71888,"twenty":-5.924891,"median":-4.16145,"eighty":-2.75929,"marketCap":151994464},{"date":"2025-10-03","current":-5.907415,"twenty":-5.938047,"median":-4.221426,"eighty":-2.76177,"marketCap":157005270},{"date":"2025-10-10","current":-5.750303,"twenty":-5.938047,"median":-4.262949,"eighty":-2.769272,"marketCap":152829598},{"date":"2025-10-17","current":-5.624613,"twenty":-5.934887,"median":-4.265883,"eighty":-2.785269,"marketCap":149489061},{"date":"2025-10-24","current":-5.247544,"twenty":-5.933303,"median":-4.296782,"eighty":-2.845783,"marketCap":139467448},{"date":"2025-10-31","current":-5.436079,"twenty":-5.924891,"median":-4.3032,"eighty":-2.870708,"marketCap":144478254},{"date":"2025-11-07","current":-4.524828,"twenty":-5.916595,"median":-4.309619,"eighty":-2.884898,"marketCap":120259356},{"date":"2025-11-14","current":-4.179182,"twenty":-5.914759,"median":-4.309619,"eighty":-2.896465,"marketCap":111072877},{"date":"2025-11-21","current":-3.550733,"twenty":-5.907415,"median":-4.304871,"eighty":-2.952238,"marketCap":94370189},{"date":"2025-11-28","current":-4.304871,"twenty":-5.907415,"median":-4.296782,"eighty":-3.104751,"marketCap":114413415},{"date":"2025-12-05","current":-3.487889,"twenty":-5.875992,"median":-4.296782,"eighty":-3.112056,"marketCap":92699920},{"date":"2025-12-12","current":-3.550733,"twenty":-5.86799,"median":-4.273096,"eighty":-3.162119,"marketCap":94370189},{"date":"2025-12-19","current":-3.582156,"twenty":-5.84457,"median":-4.262949,"eighty":-3.19281,"marketCap":95205323},{"date":"2025-12-26","current":-3.92117,"twenty":-5.843755,"median":-4.262949,"eighty":-3.21786,"marketCap":97093533},{"date":"2026-01-02","current":-3.424602,"twenty":-5.82283,"median":-4.235196,"eighty":-3.269261,"marketCap":84797846},{"date":"2026-01-09","current":-3.869801,"twenty":-5.792641,"median":-4.210604,"eighty":-3.333795,"marketCap":95821565},{"date":"2026-01-16","current":-3.698571,"twenty":-5.781725,"median":-4.16249,"eighty":-3.356755,"marketCap":91581673},{"date":"2026-01-23","current":-3.835555,"twenty":-5.769156,"median":-4.143012,"eighty":-3.358933,"marketCap":94973587},{"date":"2026-01-30","current":-3.921541,"twenty":-5.737734,"median":-4.109523,"eighty":-3.368971,"marketCap":97102724},{"date":"2026-02-06","current":-3.957191,"twenty":-5.706311,"median":-4.080473,"eighty":-3.382482,"marketCap":97985476},{"date":"2026-02-13","current":-4.206744,"twenty":-5.687458,"median":-4.063335,"eighty":-3.402348,"marketCap":104164740},{"date":"2026-02-20","current":-4.519036,"twenty":-5.682154,"median":-4.084915,"eighty":-3.42469,"marketCap":106812996},{"date":"2026-02-27","current":-4.070867,"twenty":-5.656708,"median":-4.104658,"eighty":-3.426652,"marketCap":96219972},{"date":"2026-03-06","current":-3.996173,"twenty":-5.636748,"median":-4.084915,"eighty":-3.433086,"marketCap":94454468},{"date":"2026-03-13","current":-3.398614,"twenty":-5.624613,"median":-4.070867,"eighty":-3.433086,"marketCap":80330435},{"date":"2026-03-20","current":-2.579959,"twenty":-5.624613,"median":-4.059951,"eighty":-3.389732,"marketCap":60980510},{"date":"2026-03-27","current":-2.020495,"twenty":-5.620211,"median":-4.053963,"eighty":-3.356755,"marketCap":47756885},{"date":"2026-04-02","current":-2.420485,"twenty":-5.602604,"median":-4.04849,"eighty":-3.19281,"marketCap":57211159},{"date":"2026-04-10","current":-2.464929,"twenty":-5.593191,"median":-4.028492,"eighty":-3.034103,"marketCap":58261634},{"date":"2026-04-17","current":-3.007213,"twenty":-5.593191,"median":-4.027305,"eighty":-2.91411,"marketCap":71079194},{"date":"2026-04-24","current":-3.65183,"twenty":-5.573117,"median":-4.02207,"eighty":-3.007213,"marketCap":86315494},{"date":"2026-05-01","current":-3.286198,"twenty":-5.551373,"median":-4.014793,"eighty":-3.009828,"marketCap":77673351},{"date":"2026-05-08","current":-3.364628,"twenty":-5.543629,"median":-3.993409,"eighty":-3.034103,"marketCap":79527131},{"date":"2026-05-15","current":-3.676105,"twenty":-5.530346,"median":-3.975555,"eighty":-3.099835,"marketCap":86889283},{"date":"2026-05-22","current":-1.721465,"twenty":-5.514142,"median":-3.957191,"eighty":-2.91411,"marketCap":73180144}],"updateTime":1779801361345},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTOR\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1171278400","title":"Citius Oncology, Inc. 獲得高達3650萬美元債務及股權資本，以加速Lymphir®商業化進程","url":"https://stock-news.laohu8.com/highlight/detail?id=1171278400","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171278400?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 08:00","pubTimestamp":1778025620,"startTime":"0","endTime":"0","summary":"Citius Oncology, Inc. 已成功获得高达3650万美元的融资组合，该笔资金包含债务与股权资本，将专项用于加速其核心产品Lymphir®的商业化布局。此次资本注入有望为公司在肿瘤治疗领域的市场拓展提供强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119011859","title":"Citius Oncology公布Lymphir™聯合帕博利珠單抗治療復發或難治性婦科癌研究者發起的1期研究積極頂線結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1119011859","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119011859?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 20:48","pubTimestamp":1773146891,"startTime":"0","endTime":"0","summary":"Citius Oncology宣布，其Lymphir™联合帕博利珠单抗治疗复发或难治性妇科癌的研究者发起1期临床试验获得了积极的顶线结果。该研究旨在评估该联合疗法的安全性、耐受性及初步疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTXR","BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616518475","title":"BUZZ-Citius公司因淋巴瘤藥物在接受CAR-T療法前顯示出對患者的益處而上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2616518475","media":"路透中文","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616518475?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 23:08","pubTimestamp":1772636914,"startTime":"0","endTime":"0","summary":"** 2025 年股价下跌约 13%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL4S3ZS1GU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4007","BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100741136","title":"Citius Oncology Inc一期臨床試驗顯示：總體緩解率達86%，完全緩解率57%，部分緩解率29%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100741136","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100741136?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 22:17","pubTimestamp":1772633851,"startTime":"0","endTime":"0","summary":"生物制药公司Citius Oncology Inc近日公布其一期临床试验数据，结果显示患者总体缓解率（ORR）达到86%。其中完全缓解（CR）比例为57%，部分缓解（PR）比例为29%。该数据凸显了其在研疗法的潜在疗效。\n临床试验采用分阶段设计，针对特定适应症患者群体进行评估。研究人员观察到治疗组在主要终点指标上表现突出，安全性数据亦符合预期标准。这些初步结果将为后续临床开发策略提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126885841","title":"Lymphir在I期研究中耐受性良好，未觀察到劑量限制性毒性","url":"https://stock-news.laohu8.com/highlight/detail?id=1126885841","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126885841?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 22:16","pubTimestamp":1772633804,"startTime":"0","endTime":"0","summary":"在CITIUS ONCOLOGY INC（简称CTOR）开展的I期临床研究中，其候选药物Lymphir展现出良好的安全性与耐受性。研究结果显示，在整个试验过程中，未观察到任何剂量限制性毒性事件，为后续临床开发奠定了坚实基础。这一积极数据进一步增强了该药物在肿瘤治疗领域的应用潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158577391","title":"Citius Oncology公布Lymphir™（E7777）在高危瀰漫性大B細胞淋巴瘤商用CAR-T療法前給藥的1期研究初步頂線數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1158577391","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158577391?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 22:16","pubTimestamp":1772633771,"startTime":"0","endTime":"0","summary":"Citius Oncology, Inc. 宣布了其针对高危弥漫性大B细胞淋巴瘤患者的研究初步顶线数据。该1期临床试验旨在评估Lymphir™（研发代码E7777）在商用嵌合抗原受体T细胞疗法之前给药的安全性与初步疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122767016","title":"Citius Oncology與Uniphar達成獨家協議 將淋巴瘤藥物Lymphir™分銷版圖擴展至歐盟","url":"https://stock-news.laohu8.com/highlight/detail?id=1122767016","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122767016?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 21:03","pubTimestamp":1770815018,"startTime":"0","endTime":"0","summary":"生物制药企业Citius Oncology宣布与欧洲领先医疗产品服务商Uniphar签署独家分销协议，正式将其创新淋巴瘤疗法Lymphir™的商业化版图拓展至欧盟市场。\n此次合作将依托Uniphar在欧洲建立的成熟分销网络，加速Lymphir™在欧盟地区的准入进程。该协议不仅强化了Citius Oncology的全球化战略布局，也为欧洲患者提供了更前沿的治疗选择。\nLymphir™作为针对特定淋巴瘤亚型的靶向疗法，此前已在部分国际市场展现出临床潜力。通过本次渠道拓展，Citius Oncology有望进一步提升其在肿瘤治疗领域的国际影响力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CTOR","CTXR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606759209","title":"Citius Oncology, Inc.盤中異動 早盤股價大跌5.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606759209","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606759209?lang=zh_tw&edition=fundamental","pubTime":"2026-01-27 22:33","pubTimestamp":1769524383,"startTime":"0","endTime":"0","summary":"北京时间2026年01月27日22时33分，Citius Oncology, Inc.股票出现异动，股价快速下挫5.42%。Citius Oncology, Inc.股票所在的制药行业中，整体涨幅为0.50%。其相关个股中，苏轩堂、Flora Growth Corp.、Apimeds Pharmaceuticals Us, Inc.涨幅较大，苏轩堂、Akanda Corp.、Flora Growth Corp.较为活跃，换手率分别为28.60%、5.54%、4.19%，振幅较大的相关个股有Flora Growth Corp.、Akanda Corp.、苏轩堂，振幅分别为17.09%、8.40%、8.39%。Citius Oncology, Inc.公司简介：Citius Oncology Inc是一家专注于开发和商业化靶向肿瘤疗法的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012722330397a3a35c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012722330397a3a35c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FLGC","ZSTK","BK4183","BK4139","CTOR","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603769320","title":"Citius Oncology, Inc.盤中異動 大幅拉升5.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603769320","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603769320?lang=zh_tw&edition=fundamental","pubTime":"2026-01-13 22:42","pubTimestamp":1768315358,"startTime":"0","endTime":"0","summary":"北京时间2026年01月13日22时42分，Citius Oncology, Inc.股票出现波动，股价急速上涨5.61%。Citius Oncology, Inc.股票所在的制药行业中，整体跌幅为0.43%。其相关个股中，Im Cannabis Corp.、Biofrontera Inc.、Citius Oncology, Inc.涨幅较大，Akanda Corp.、Gelteq Limited、苏轩堂较为活跃，换手率分别为14.79%、5.41%、4.31%，振幅较大的相关个股有脑再生科技、大自然药业、Biofrontera Inc.，振幅分别为16.55%、11.06%、10.04%。Citius Oncology, Inc.公司简介：Citius Oncology Inc是一家专注于开发和商业化靶向肿瘤疗法的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011322423897a1a7b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011322423897a1a7b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601842432","title":"Citius Oncology, Inc.盤中異動 早盤急速下挫6.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601842432","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601842432?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 22:32","pubTimestamp":1767709948,"startTime":"0","endTime":"0","summary":"北京时间2026年01月06日22时32分，Citius Oncology, Inc.股票出现异动，股价急速跳水6.96%。Citius Oncology, Inc.股票所在的制药行业中，整体涨幅为0.33%。其相关个股中，Caring Brands, Inc.、Gelteq Limited、脑再生科技涨幅较大，Akanda Corp.、Redhill Biopharma Ltd、Cbdmd, Inc.较为活跃，换手率分别为14.13%、3.33%、0.81%，振幅较大的相关个股有Caring Brands, Inc.、脑再生科技、Akanda Corp.，振幅分别为8.86%、6.33%、5.22%。Citius Oncology, Inc.公司简介：Citius Oncology Inc是一家专注于开发和商业化靶向肿瘤疗法的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106223228953c16f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106223228953c16f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595500753","title":"Citius Oncology, Inc.盤中異動 早盤大幅下挫5.31%報1.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595500753","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595500753?lang=zh_tw&edition=fundamental","pubTime":"2025-12-29 22:48","pubTimestamp":1767019725,"startTime":"0","endTime":"0","summary":"北京时间2025年12月29日22时48分，Citius Oncology, Inc.股票出现波动，股价大幅跳水5.31%。Citius Oncology, Inc.股票所在的制药行业中，整体涨幅为0.09%。其相关个股中，Caring Brands, Inc.、Akanda Corp.、脑再生科技涨幅较大，Akanda Corp.、大自然药业、Cbdmd, Inc.较为活跃，换手率分别为117.47%、6.59%、5.20%，振幅较大的相关个股有Caring Brands, Inc.、脑再生科技、Cbdmd, Inc.，振幅分别为31.25%、18.85%、11.78%。Citius Oncology, Inc.公司简介：Citius Oncology Inc 是一家专业制药公司，致力于开发和商业化针对未满足需求的重症监护产品，专注于肿瘤产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229224845a4868ab8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229224845a4868ab8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CABR","BK4183","BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194721703","title":"Citius Oncology完成1800萬美元的同時註冊直接發行和私募配售，價格符合納斯達克規則","url":"https://stock-news.laohu8.com/highlight/detail?id=1194721703","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194721703?lang=zh_tw&edition=fundamental","pubTime":"2025-12-11 05:31","pubTimestamp":1765402278,"startTime":"0","endTime":"0","summary":"Citius Oncology完成1800万美元的同时注册直接发行和私募配售，价格符合纳斯达克规则","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186772713","title":"Citius Oncology Inc - 直接發行以每股1.09美元購買1,284,404股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1186772713","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186772713?lang=zh_tw&edition=fundamental","pubTime":"2025-12-09 21:33","pubTimestamp":1765287209,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc - 直接发行以每股1.09美元购买1,284,404股普通股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR","CTXR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111513577","title":"Citius Oncology 宣佈以市場定價進行1800萬美元的註冊直銷及私人投資","url":"https://stock-news.laohu8.com/highlight/detail?id=1111513577","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111513577?lang=zh_tw&edition=fundamental","pubTime":"2025-12-09 21:31","pubTimestamp":1765287103,"startTime":"0","endTime":"0","summary":"Citius Oncology 宣布以市场定价进行1800万美元的注册直销及私人投资","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4007","BK4139","CTXR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178681935","title":"Citius Oncology通過與Er-Kim的獨家協議擴展Lymphir™在土耳其和中東國家的分銷","url":"https://stock-news.laohu8.com/highlight/detail?id=1178681935","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178681935?lang=zh_tw&edition=fundamental","pubTime":"2025-12-04 21:37","pubTimestamp":1764855430,"startTime":"0","endTime":"0","summary":"Citius Oncology通过与Er-Kim的独家协议扩展Lymphir™在土耳其和中东国家的分销","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4007","BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108685707","title":"Citius Oncology 宣佈 Lymphir™ 上市，作為切膚性 T 細胞淋巴瘤的新型癌症免疫療法","url":"https://stock-news.laohu8.com/highlight/detail?id=1108685707","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108685707?lang=zh_tw&edition=fundamental","pubTime":"2025-12-02 01:01","pubTimestamp":1764608490,"startTime":"0","endTime":"0","summary":"Citius Oncology 宣布在美国商业化推出 Lymphir™，这是一种针对切肤性 T 细胞淋巴瘤的新型癌症免疫疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTXR","BK4007","CTOR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}